Aclaris Therapeutics, INC 10-Q quarterly reports

Aclaris Therapeutics reports increased R&D expenses and net losses in Q2 2026, driven by clinical trial advancements, while securing $57.9 million in financing.

Aclaris Therapeutics reported increased revenue and a wider net loss in its Q1 2026 filing, with significant investment in R&D for its immuno-inflammatory disease pipeline.

Aclaris Therapeutics, Inc. reported a significantly wider net loss in the third quarter and first nine months of 2025, driven by increased research and development expenses, despite positive clinical progress for its pipeline candidates.

Aclaris Therapeutics, a clinical-stage biopharmaceutical company, reported an increased net loss and decreased revenue for Q2 2025, driven by higher R&D expenses for key drug candidates and lower licensing income, while maintaining sufficient liquidity for over 12 months.

Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced its Q1 2025 financial results, highlighting a net loss of $15.1 million and progress in its immuno-inflammatory disease pipeline.

Aclaris Therapeutics announced its third quarter 2024 financial results, alongside updates on its strategic review and clinical development programs.

Aclaris Therapeutics, a clinical-stage biopharmaceutical company, announced its second quarter 2024 financial results, highlighting a strategic review of its business and progress in its drug development programs.

Aclaris Therapeutics reported a net loss of $16.9 million for the first quarter of 2024, alongside updates on its drug development programs and strategic review.